Research/Clinical Trials at The Cancer Center at Saint Barnabas Medical Center New Jersey

Research / Clinical Trials

Our medical staff is committed to offering the most up-to-date treatments available. Most of these will be available at Saint Barnabas Medical Center, although there may be times we recommend that you consider a very specialized treatment which may be available only at another center. In addition, to broaden your treatment options, we will inform you of any clinical trials for which you may be eligible. Our Center is involved in many clinical trials run both by the National Cancer Institute and by individual pharmaceutical companies. Today's clinical trials lead to tomorrow's breakthrough treatments.

For more information on clinical trials, please contact our Research Manager at (973) 322-2527.
Research Nurse at (973) 322-5172.

Breast Cancer Trials Stage I, II, III
Breast Cancer Trials Metastatic
Gastrointestinal STAGE I, II, III
Gastrointestinal Metastatic
Genitourinary
Gynecological Cancers
Multiple Myeloma
Ovarian
Primary Brain / Central Nervous System
Symptom Management / Cancer Prevention Protocols

Breast Cancer Trials Stage I, II, III
E5103	A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
NSABP B-39	A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
CTSU PACCT-1Tailor	Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial
CTSU S0307	Phase III Trial of Bisphosphonates ( Zoledronic acid Vs. Clodronate Vs. Ibandronate) as Adjuvant Therapy for Primary Breast Cancer.
SWOG S0221	Phase III trial of Continuous schedule AC+GCSF Vs every 2 week schedule AC, followed by Paclitaxel given either Every 2 weeks or weekly for 12 weeks as Post operative adjuvant therapy in node positive or high risk node negative breast.
CTSU IBSCG24-02 SOFT	A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer (TEXT)
NSABP B-42	A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer
NCCTG N063D/ALTTO	Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Study: A randomized, multi-center, open-label, phase III study of adjuvant Lapatinib, Trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer.
CALGB 369901	Observational Cohort Study: chemotherapy decisions and outcomes in women age 65 or older with operable, newly diagnoses breast cancer.
[ top ]

Breast Cancer Trials Metastatic
CZOL446E2352	A prospective, randomized, stratified, placebo-controlled, multi-center, 2-arm trial of the continued efficacy and safety of Zometa (every 4 weeks vs. every 12 weeks) in patients with documented bone metastases from breast cancer.
TOC4129g	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer
CALGB 40302	Endocrine Therapy With or Without Inhibition of EGF & HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant with or without Lapatanib for Postmenopausal Women with ER &/or PR Positive Advanced Breast Cancer
[ top ]
Gastrointestinal STAGE I, II, III
CALGB80101	Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma
CTSU E5202	A Randomized Phase III Study Comparing 5-FU Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers
CTSU N0147	A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer
RAD001-CRAD001C2324	A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine tumor (NET)
[ top ]
Gastrointestinal Metastatic
NSABP C-10	A Phase II Trial of mFOLFOX6 Chemotherapy Plus Bevacizumab for Patients with Unresectable Stage IV Colon Cancer and a Synchronous Asymptomatic Primary Tumor
S0600	SUSPENDED - Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab with or without Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on (1st line) Bevacizumab with either FOLFOX, OPTIMOX or XELOX
[ top ]
Genitourinary
CTSU E2805	A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib vs Sorafenib vs Placebo in Patients with Resected Renal Cell Carcinoma
RTOG 0232	A Phase III Study Comparing Combined External Beam Radiation AND Transperineal Intestitial Permanent Brachytherapy With Brachytherapy Alone For Selected Patients With Intermediate Risk Prostatic Carcinoma
RTOG 0415	A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients Treated for Favorable-Risk Prostate Cancer
RTOG 0534	A phase III trial of short term androgen deprivation with pelvic lymph node or prostate bed only radiotherapy (SPPORT) in prostate cancer patients with a rising PSA after radical prostatectomy.
[ top ]
Gynecological Cancers
GOG0209	Randomized Phase III Trial of DOXORUBICIN/CISPLATIN/PACLITAXEL And G-CSF Versus CARBOPLATIN/PACLITAXEL In Patients With Stage III & IV Or Recurrent Endometrial Cancer
RTOG 0417	A phase II study of bevacizumab in combination with definitive radiotherapy and Cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma.
Multiple Myeloma
C05009	Randomized Ph3 study of 3 Novel treatment regimens in subjects with previously untreated multiple myeloma who are not considered candidates for high dose chemotherapy and autologous stem cell transplantation: Velcade (Bortezomib), Thalomid (Thalidomide), and Dexamethasone (VTD) vs. Velcade and Dexamethasone (VD) vs. Velcade, Melphalan, and Prednisone (VMP)
Ovarian
AVF4095g	A Phase III, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Platinum-Sensitive Recurrent Ovary, Primary Peritoneal or Fallopian Tube Carcinoma
CTSU GOG0218	A Phase III Trial of Carboplatin and Paclitaxel plus placebo versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab followed by placebo,VS. Carboplatin and Paclitaxel plus Concurrent and Extended Bevacizumab in Women with Newly Diagnosed, Previously Untreated Suboptimal Advanced Stage Epithelial Ovarian and Primary Peritoneal Cancer
[ top ]
Primary Brain / Central Nervous System
RTOG 0424	A phase II study of a Temozolomide based chemoradiotherapy regimen for high risk low grade gliomas.
Symptom Management / Cancer Prevention Protocols
RTOG 0614	A phase III randomized study of memantine hydrochloride in preventing cognitive dysfunction in patients undergoing whole brain radiotherapy for brain metastases secondary to solid tumors.

[ top ] [ Back to Patient Care Services ]